HONG KONG, 11 April 2025 – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, is pleased to announce that the first patient was recently enrolled in the Phase II clinical trial of one of Zhaoke’s core drug candidates, BRIMOCHOLTM PF, an innovative treatment for presbyopia. At the same time, the Company is also delighted to announce a partnership with Lunatus Marketing & Consulting FZCO (“Lunatus”) based in Dubai (UAE), a leading pharmaceutical company in the Middle East and North Africa region, for the commercialization of BRIMOCHOLTM PF in the Gulf Cooperation Council (“GCC”) countries.
Simultaneously with advancing the clinical development of BRIMOCHOLTM PF, Zhaoke Ophthalmology is excited to announce the third out-licensing deal for BRIMOCHOLTM PF, opening a new market for its drug.
On 21 March 2025, Zhaoke Ophthalmology entered into a distribution and supply agreement with Lunatus for the commercialization of BRIMOCHOLTM PF in the GCC countries. Under the terms of the agreement, Zhaoke Ophthalmology will grant Lunatus the exclusive rights to import, distribute, promote, market and sell BRIMOCHOLTM PF in the Kingdom of Saudi Arabia, the UAE, Kuwait, Oman, Bahrain, and Qatar. As part of the agreement, Lunatus will obtain the relevant local drug registrations on behalf of the Company. Zhaoke will be eligible to receive milestone payments based on certain achievements.
Previously, Zhaoke Ophthalmology established partnerships with Kwangdong Pharmaceutical Co., Ltd., a leading Korean pharmaceutical company, and AFT Pharmaceuticals Limited, a leading manufacturer and distributor of healthcare products based in New Zealand, for the commercialization of BRIMOCHOLTM PF in the South Korean market and the ANZ (Australia and New Zealand) markets respectively.
02-05-2025
By